toxicokinetics

Oncology

Successfully navigating the process for drugs with a higher risk-benefit ratio requires a tailored non-clinical programme design.

Oncology

Dr Li Mao and Dr Giovanni Selvaggi of Betta Pharmaceuticals and Xcovery Holdings discuss their novel ALK inhibitor and the Chinese biotech landscape.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.